IGF1R and non-small cell lung carcinoma: Moreover, IGF-1/IGF-1R antibodies are well tolerated in clinical trials but fail to generate overall therapeutic advantages in patients with small cell lung cancer or in patients with non-small cell lung cancer by combination with chemotherapy or tyrosine kinase inhibitors (TKIs) [12–16, 269].